Shuyan Wang - Concepedia

Author

Shuyan Wang

Also Known As

S Y Wang, SHU-YAN WANG, SHUYAN WANG, Shu-Yan Wang, Shu-yan Wang, Shujing Zhang, Shuyan WANG, Shuyan Wang, Wang, Shu-Yan, Wang, Shuyan

154

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Peking University Peking University Cancer Hospital Anhui Provincial Hospital Zhejiang University Shanghai Chest Hospital

About

Shuyan Wang is an author at Peking University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	789
2	Health Sciences	5	5	498
3	Engineering	3	3	66
4	Education	1	1	72
5	Language Studies	1	1	72

Shuyan Wang

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11) Yunpeng Yang, Zhehai Wang, Jian Fang, Journal of Thoracic Oncology	2020	376
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Shun Lü, Lin Wu, Hong Jian, The Lancet Oncology OncologyFirst Interim ResultsBevacizumab Biosimilar Ibi305Clinical TrialsPathology	2022	227
Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. Timothy R. DeGrado, Robert E. Reiman, David T. Price, PubMed	2002	181
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial Shun Lü, Lin Wu, Hong Jian, The Lancet Respiratory Medicine OncologyDisease ProgressionSecond Interim AnalysisMetronomic TherapyClinical Trials	2023	181
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study Yunpeng Yang, Jiya Sun, Zhehai Wang, Journal of Thoracic Oncology	2021	141
Space-like 56Fe irradiation manifests mild, early sex-specific behavioral and neuropathological changes in wildtype and Alzheimer’s-like transgenic mice Bin Liu, Robert G. Hinshaw, Kevin X. Le, Scientific Reports	2019	75
Adopting Cell Phones in EFL Teaching and Learning Guoqiang Cui, Shuyan Wang Journal of Educational Technology Development and Exchange Second Language LearningE-learningMultilingualismEducationLanguage Learning	2008	72
Synthesis and preliminary evaluation of 18F-labeled 4-thia palmitate as a PET tracer of myocardial fatty acid oxidation Timothy R. DeGrado, Shuyan Wang, James E. Holden, Nuclear Medicine and Biology Lipid Analysis18F-labeled 4-Thia PalmitateBiochemistryPreliminary EvaluationPet Tracer	2000	67
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study Li Zhang, Zhehai Wang, Jian Fang, Lung Cancer Orient-11 StudyMedicineMetastatic Nonsquamous NsclcMetronomic TherapyClinical Trials	2022	66
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial Haiping Jiang, Yulong Zheng, Jiong Qian, BMC Cancer	2020	62

Page 1